Skip to main content

Osmetech Raises $8.6M Through Private Placement

NEW YORK (GenomeWeb News) – British molecular diagnostics firm Osmetech has raised £5.2 million ($8.6 million) through a private placement of around 262 million new ordinary shares at a price of 2p each.

The new shares represent nearly 30 percent of the firm's now existing issued share capital. The placement was made last week.

Among the investors in the placement are the Efficacy Biotech Master Fund Ltd. and its affiliates, Gartmore and Schroder, the firm's principal shareholders, and certain new investors in the US.

Osmetech intends to use proceeds from the placement to fund continued development and regulatory clearance for further tests for its eSensor XT-8 System, and to fund sales and marketing efforts for the system and new tests.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.